Compare Aurobindo Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ASTRAZENECA PHARMA AUROBINDO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 6.7 99.2 6.8% View Chart
P/BV x 1.6 15.4 10.5% View Chart
Dividend Yield % 0.7 0.1 925.9%  

Financials

 AUROBINDO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
ASTRAZENECA PHARMA
Mar-21
AUROBINDO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0234,970 20.6%   
Low Rs3332,348 14.2%   
Sales per share (Unadj.) Rs422.8325.4 129.9%  
Earnings per share (Unadj.) Rs92.037.3 246.4%  
Cash flow per share (Unadj.) Rs110.045.4 242.4%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Avg Dividend yield %0.60.1 1,079.0%  
Book value per share (Unadj.) Rs374.3181.8 205.8%  
Shares outstanding (eoy) m585.9425.00 2,343.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.611.2 14.3%   
Avg P/E ratio x7.498.0 7.5%  
P/CF ratio (eoy) x6.280.6 7.6%  
Price / Book Value ratio x1.820.1 9.0%  
Dividend payout %4.35.4 81.2%   
Avg Mkt Cap Rs m397,39891,478 434.4%   
No. of employees `000NANA-   
Total wages/salary Rs m35,3502,195 1,610.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m247,7468,136 3,045.2%  
Other income Rs m3,809128 2,966.1%   
Total revenues Rs m251,5558,264 3,044.0%   
Gross profit Rs m81,4801,355 6,014.6%  
Depreciation Rs m10,554201 5,242.9%   
Interest Rs m74511 6,833.9%   
Profit before tax Rs m73,9901,271 5,821.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,098338 5,947.8%   
Profit after tax Rs m53,892933 5,776.2%  
Gross profit margin %32.916.7 197.5%  
Effective tax rate %27.226.6 102.2%   
Net profit margin %21.811.5 189.7%  
BALANCE SHEET DATA
Current assets Rs m198,2356,887 2,878.4%   
Current liabilities Rs m106,6523,734 2,856.0%   
Net working cap to sales %37.038.8 95.4%  
Current ratio x1.91.8 100.8%  
Inventory Days Days1945 42.5%  
Debtors Days Days5238 135.0%  
Net fixed assets Rs m135,7781,855 7,319.2%   
Share capital Rs m58650 1,171.8%   
"Free" reserves Rs m218,7134,496 4,864.8%   
Net worth Rs m219,2994,546 4,824.2%   
Long term debt Rs m1,6840-   
Total assets Rs m334,0138,742 3,820.8%  
Interest coverage x100.3117.6 85.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 79.7%   
Return on assets %16.410.8 151.5%  
Return on equity %24.620.5 119.7%  
Return on capital %33.828.2 119.9%  
Exports to sales %53.80-   
Imports to sales %16.429.3 56.0%   
Exports (fob) Rs m133,248NA-   
Imports (cif) Rs m40,6152,382 1,705.1%   
Fx inflow Rs m133,248318 41,941.4%   
Fx outflow Rs m44,9462,382 1,886.9%   
Net fx Rs m88,302-2,064 -4,277.6%   
CASH FLOW
From Operations Rs m33,2891,048 3,177.1%  
From Investments Rs m5,9871,730 346.0%  
From Financial Activity Rs m-13,648-90 15,215.3%  
Net Cashflow Rs m25,8312,688 960.8%  

Share Holding

Indian Promoters % 48.8 0.0 -  
Foreign collaborators % 3.1 75.0 4.1%  
Indian inst/Mut Fund % 37.9 3.5 1,075.6%  
FIIs % 21.4 2.4 897.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 25.0 192.7%  
Shareholders   341,568 62,183 549.3%  
Pledged promoter(s) holding % 24.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

SGX Nifty Tanks 294 Points, Maruti Suzuki Quarterly Results, Oyo's Rs 84 bn IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note on Tuesday. Benchmark indices snapped their five-day losing run and ended on a positive note in a highly volatile session.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 45.0% (Quarterly Result Update)

Aug 11, 2021 | Updated on Aug 11, 2021

For the quarter ended June 2021, ASTRAZENECA PHARMA has posted a net profit of Rs 102 m (down 45.0% YoY). Sales on the other hand came in at Rs 2 bn (down 9.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 27, 2022 09:23 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS